Filing Flows › Heron Therapeutics (HRTX) › How it makes money
How Heron Therapeutics (HRTX) makes money
Heron Therapeutics (HRTX) made $37.7M of revenue in the second quarter 2026 (Q2 2026), +1% from a year earlier. CINVANTI brought in $21.8M (58%); ZYNRELEF brought in $11.1M (29%); Aponvie brought in $4.3M (11%).
Drawing the Sankey…
Revenue by segment, Q2 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| CINVANTI | $21.8M | 57.9% | +6% | -10% |
| ZYNRELEF | $11.1M | 29.4% | +8% | +35% |
| Aponvie | $4.3M | 11.4% | +26% | +74% |
| SUSTOL | $540K | 1.4% | -1% | -78% |
Where each dollar of revenue goes
| Line | Q2 2026 | % of revenue |
|---|---|---|
| Revenue | $37.7M | 100.0% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q2 2026 | $37.7M | +1% |
| Q1 2026 | $34.7M | -11% |
| Q4 2025 | $40.6M | -0.5% |
| Q3 2025 | $38.2M | +16% |
| Q2 2025 | $37.2M | +3% |
| Q1 2025 | $38.9M | +12% |
| Q4 2024 | $40.8M | +19% |
From Heron Therapeutics' 10-Q filed Aug 10, 2026 (on EDGAR).
Questions
How does Heron Therapeutics make money?
Heron Therapeutics (HRTX) made $37.7M of revenue in the second quarter 2026 (Q2 2026), +1% from a year earlier. CINVANTI brought in $21.8M (58%); ZYNRELEF brought in $11.1M (29%); Aponvie brought in $4.3M (11%).
What is Heron Therapeutics' biggest business?
CINVANTI: $21.8M in the second quarter 2026, 58% of revenue, -10% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.